title: Simultaneous administration of oral rhesus-human reassortant tetravalent (RRV-TV) rotavirus vaccine and oral poliovirus vaccine (OPV) in Thai infants.
abstract: Rhesus-human reassortant tetravalent (RRV-TV) oral rotavirus vaccine was given at the same time as oral poliovirus vaccine (OPV) or inactivated parenteral poliovirus vaccine (IPV) to Thai infants at 2, 4 and 6 months of age. Sera for rotavirus antibody studies were taken prior to and one month after each vaccination. After the first dose of vaccine at 2 months of age, 37% of the infants receiving rotavirus vaccine with IPV but only 10% of those receiving it with OPV showed a seroconversion by rotavirus IgA ELISA antibody test (p < 0.001). Likewise, neutralizing antibody seroconversion rates in initially seronegative subjects to rhesus rotavirus type 3 (RRV-3) after the first dose of RRV-TV vaccine were higher if the vaccine was given with IPV (74%) than if given with OPV (39%) (p = 0.0069). After the second and third doses of vaccine, the rotavirus IgA ELISA and RRV-3-neutralizing antibody response rates were not different between groups. Development of neutralizing antibodies to human rotavirus serotypes 1, 2 and 4 in the first seven months of life in vaccinees receiving rotavirus vaccine with OPV tended to occur at a lower rate than in those receiving rotavirus vaccine with IPV but the antibody levels were not significantly different at 7 months of age. Poliovirus type 2 and type 3 antibody responses were not different in infants receiving the rotavirus vaccine with OPV as compared with infants receiving only OPV. The mean poliovirus type 1 antibody level was slightly but not significantly lower at 5 and 7 months of age in infants that received both rotavirus vaccine and OPV.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Tropical Medicine, Mahidol University, Bangkok, Thailand.
authors.forename: S
authors.initials: S
authors.lastname: Migasena
authors.forename: S
authors.initials: S
authors.lastname: Simasathien
authors.forename: R
authors.initials: R
authors.lastname: Samakoses
authors.forename: P
authors.initials: P
authors.lastname: Pitisuttitham
authors.forename: P
authors.initials: P
authors.lastname: Sangaroon
authors.forename: G
authors.initials: G
authors.lastname: van Steenis
authors.forename: E C
authors.initials: EC
authors.lastname: Beuvery
authors.forename: H
authors.initials: H
authors.lastname: Bugg
authors.forename: R
authors.initials: R
authors.lastname: Bishop
authors.forename: B L
authors.initials: BL
authors.lastname: Davidson
mesh_terms: D000284:Administration, Oral; D000704:Analysis of Variance; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008253:Macaca mulatta / Q000276:immunology; D017955:Poliovirus / Q000276:immunology; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage*; D012401:Rotavirus / Q000276:immunology; D022243:Rotavirus Vaccines; D013785:Thailand; D014613:Vaccines, Attenuated / Q000008:administration & dosage*; D014765:Viral Vaccines / Q000008:administration & dosage*
chemical_list: D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral; D022243:Rotavirus Vaccines; D014613:Vaccines, Attenuated; D014765:Viral Vaccines; C052014:rhesus rotavirus vaccine